²é¿´: 4536  |  »Ø¸´: 69
¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û60´Î£¬×÷Õßzhuimengren639Ôö¼Ó½ð±Ò 56.5 ¸ö
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

[×ÊÔ´] ·ÖÏí£ºµÂ¹úº£µÂ±¤´óѧHugo Kubinyi½ÌÊÚµÄÒ©ÎïÉè¼ÆµÄ¿Î¼þ

µÂ¹úUniversity of HeidelbergµÄÖøÃûÒ©Îﻯѧ¼ÒHugo Kubinyi¹ØÓÚÒ©ÎïÉè¼ÆµÄ¿Î¼þ£¬ÏàÐŶԸãÒ©ÎïÉè¼ÆµÄͬѧ»áÓÐÓõġ£

Èç¹û¸Ð¾õµ¥¸öÏÂÔØÌ«Âé·³£¬ÄÇô¿ÉÒÔÓà flashget/ѸÀ×ÅúÁ¿ÏÂÔØ£¬Ï£Íû´ó¼ÒÄܹ»Ï²»¶£¬Ó»Ô¾ÆÀÂÛ£¡

¿´µ½ÓÐÕâô¶à³æÓÑϲ»¶Õâ¸ö¿Î¼þ£¬ÎªÁ˸Ðл´ó¼Ò£¬ÎÒ°ÑÎÒÏÂÔØµÄ´«µ½ÄÉÃ×ÅÌÉϹ©´ó¼ÒÏÂÔØ£¬µØÖ·ÈçÏÂ
http://www.namipan.com/d/Hugo%20 ... c4504bad9361a9db300


ÄÚÈÝ:

Drug Discovery (758 kBlack Eye
http://www.kubinyi.de/dd-01.pdf

Serendipity and Rational Design (374 kBlack Eye
http://www.kubinyi.de/dd-02.pdf

Chemogenomics (1,453 kBlack Eye
http://www.kubinyi.de/dd-03.pdf

Ligand-Receptor Interactions (647 kBlack Eye
http://www.kubinyi.de/dd-04.pdf

Hydrogen Bonds and Biological Activities (359 kBlack Eye
http://www.kubinyi.de/dd-05.pdf

Chemical Similarity and Biological Activities (686 kBlack Eye
http://www.kubinyi.de/dd-06.pdf

Drug Metabolism (501 kBlack Eye
http://www.kubinyi.de/dd-07.pdf

Peptidomimetics and Prodrugs (294 kBlack Eye
http://www.kubinyi.de/dd-08.pdf

Combinatorial Chemistry Technology (147 kBlack Eye
http://www.kubinyi.de/dd-09.pdf

Combinatorial Chemistry in Drug Research (215 kBlack Eye
http://www.kubinyi.de/dd-10.pdf

QSAR Parameters (284 kBlack Eye
http://www.kubinyi.de/dd-11.pdf

QSAR - Hansch and Free Wilson Analyses (153 kBlack Eye
http://www.kubinyi.de/dd-12.pdf

Variable Selection and Model Validation (935 kBlack Eye
http://www.kubinyi.de/dd-13.pdf

Nonlinear QSAR and 3D QSAR (173 kBlack Eye
http://www.kubinyi.de/dd-14.pdf

QSAR Examples (138 kBlack Eye
http://www.kubinyi.de/dd-15.pdf

Structure-Based Ligand Design (782 kBlack Eye
http://www.kubinyi.de/dd-16.pdf

Computer-Aided Ligand Design (850 kBlack Eye
http://www.kubinyi.de/dd-17.pdf

Pharmacophore Analyses (486 kBlack Eye
http://www.kubinyi.de/dd-18.pdf

Virtual Screening (299 kBlack Eye
http://www.kubinyi.de/dd-19.pdf

Combinatorial and Fragment-Based Ligand Design (945 kBlack Eye
http://www.kubinyi.de/dd-20.pdf

Serine Proteases and their Inhibitors (371 kBlack Eye
http://www.kubinyi.de/dd-21.pdf

Thrombin Inhibitor Design (332 kBlack Eye
http://www.kubinyi.de/dd-22.pdf

Problems in Drug Design (1,043 kBlack Eye
http://www.kubinyi.de/dd-23.pdf

In Search for New Leads
http://www.kubinyi.de/paris-07-05.pdf

From Leads to Drugs
http://www.kubinyi.de/wien-06-05.pdf

Validation and Predictivity of QSAR Models
http://www.kubinyi.de/istanbul-2004-lecture.pdf

[ Last edited by zhuimengren639 on 2008-10-25 at 22:39 ]
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

gp0713

Òø³æ (СÓÐÃûÆø)


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

very good£¡thanks£¡
3Â¥2008-10-24 21:59:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 70 ¸ö»Ø´ð

xufund

ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

very good
thanks
2Â¥2008-10-24 21:09:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lijianyong

½ð³æ (ÕýʽдÊÖ)


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

ºÃµÄºÜ°¡
лл
ÓйØÒ©ÎïÉè¼Æ¶¼»¶Ó­
5Â¥2008-10-25 03:15:15
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

tnt

ľ³æ (ÖøÃûдÊÖ)


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

ÐÒ¿àÁË£¬Ð»Ð»£¡£¡
6Â¥2008-10-25 07:02:51
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¼òµ¥»Ø¸´
2008-10-24 22:03   »Ø¸´  
 
¡î ÎÞÐǼ¶ ¡ï Ò»ÐǼ¶ ¡ï¡ï¡ï ÈýÐǼ¶ ¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ²ÄÁÏѧ˶318Çóµ÷¼Á +5 February_Feb 2026-03-19 5/250 2026-03-19 23:51 by 23Postgrad
[¿¼ÑÐ] 321Çóµ÷¼Á +8 ºÎÈó²É123 2026-03-18 10/500 2026-03-19 16:46 by ºÎÈó²É123
[¿¼²©] ¶«»ªÀí¹¤´óѧ»¯²Äרҵ26½ì˶ʿ²©Ê¿ÉêÇë +8 zlingli 2026-03-13 8/400 2026-03-19 16:32 by ÇáËɲ»ÉÙËæ
[¿¼ÑÐ] Ò»Ö¾Ô¸Äϲý´óѧ£¬327·Ö£¬²ÄÁÏÓ뻯¹¤085600 +3 Ncdx123456 2026-03-19 3/150 2026-03-19 13:18 by houyaoxu
[¿¼ÑÐ] Ò»Ö¾Ô¸Ìì´ó²ÄÁÏÓ뻯¹¤£¨085600£©×Ü·Ö338 +5 ²Ì´óÃÀÅ® 2026-03-13 5/250 2026-03-19 10:44 by ÊÇСÁõѽ¡«
[¿¼ÑÐ] 274Çóµ÷¼Á +6 S.H1 2026-03-18 6/300 2026-03-19 09:34 by »¨µêÏà¼û
[¿¼ÑÐ] ±¾¿ÆÖ£ÖÝ´óѧÎïÀíѧԺ£¬Ò»Ö¾Ô¸»ª¿Æ070200ѧ˶£¬346Çóµ÷¼Á +4 ÎÒ²»ÊÇÒ»¸ù´Ð 2026-03-18 4/200 2026-03-19 09:11 by ¸¡ÔÆ166
[¿¼ÑÐ] 278Çóµ÷¼Á +5 ÑÌ»ðÏÈÓÚ´º 2026-03-17 5/250 2026-03-18 08:43 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] ¿¼ÑÐÇóµ÷¼Á +3 éÙËÌ. 2026-03-17 4/200 2026-03-17 21:43 by ÓÐÖ»ÀêÅ«
[¿¼ÑÐ] 268Çóµ÷¼Á +8 Ò»¶¨ÓÐѧÉÏ- 2026-03-14 9/450 2026-03-17 17:47 by laoshidan
[¿¼ÑÐ] 326Çóµ÷¼Á +5 Éϰ¶µÄСÆÏ 2026-03-15 6/300 2026-03-17 17:26 by ruiyingmiao
[¿¼ÑÐ] ¿¼Ñл¯Ñ§Ñ§Ë¶µ÷¼Á£¬Ò»Ö¾Ô¸985 +4 ÕÅvvvv 2026-03-15 6/300 2026-03-17 17:15 by ruiyingmiao
[¿¼ÑÐ] »úеר˶325£¬Ñ°ÕÒµ÷¼ÁԺУ +3 y9999 2026-03-15 5/250 2026-03-16 19:58 by y9999
[¿¼ÑÐ] 0703Ò»Ö¾Ô¸211 285·ÖÇóµ÷¼Á +5 ly3471z 2026-03-13 5/250 2026-03-16 16:16 by ŶŶ123
[¿¼ÑÐ] 0703 ÎïÀí»¯Ñ§µ÷¼Á +3 ÎÒ¿ÉÒÔÉϰ¶µÄ¶Ô 2026-03-13 5/250 2026-03-16 10:50 by ÎÒ¿ÉÒÔÉϰ¶µÄ¶ÔÂ
[¿¼ÑÐ] 0856Çóµ÷¼Á +3 ÁõÃÎ΢ 2026-03-15 3/150 2026-03-16 10:00 by houyaoxu
[¿¼ÑÐ] 294Çóµ÷¼Á +3 Zys010410@ 2026-03-13 4/200 2026-03-15 10:59 by zhq0425
[¿¼ÑÐ] 085601²ÄÁϹ¤³Ì315·ÖÇóµ÷¼Á +3 yang_0104 2026-03-15 3/150 2026-03-15 10:58 by peike
[¿¼ÑÐ] 288Çóµ÷¼Á +4 Ææµã0314 2026-03-14 4/200 2026-03-14 23:04 by JourneyLucky
[¿¼ÑÐ] ÕÐÊÕ0805£¨²ÄÁÏ£©µ÷¼Á +3 18595523086 2026-03-13 3/150 2026-03-14 00:33 by 123%¡¢
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û